Cleveland's Aeris Biosciences raises $3.4M seed to bring wound tech to humans
What's the deal? Aeris BiosciencesDealroom has a profile for this one. Try Dealroom →, a two-year-old Cleveland startup, has closed a $3.4 million seed round. The capital moves it closer to US Food and Drug Administration (FDA) approval and its first human trials of a wound-care technology.
What's the endgame? The company's Aer Biomaterial Platform is a bio-synthetic, highly porous material designed to help complex wounds — such as severe burns or deep cuts — heal faster. It works by supporting cell regeneration and disrupting bacterial growth, without any drugs.
Why now? Founder and chief executive officer Isaiah Kaiser called the approaching FDA milestone a "really huge" inflection point for the startup, which recently rebranded from Auxilium HealthDealroom has a profile for this one. Try Dealroom →.
How it works: "When you get a cut that is not healing, oftentimes it is not healing because bad bacteria is controlling your wound," Kaiser said. The material stops bacteria from dominating the wound, he added, "allowing your cells or skin tissue to begin healing."
The signal: Winning FDA clearance and moving to human pilots would mark the transition from lab-stage science to a testable medical product — the point where wound-care startups either validate their technology or stall.
Read more: crainscleveland.com
Image credit: Generated with Gemini
